Supplementary Tables S1-S10 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

S1: Motif enrichment results around differentially methylated sites in CRPC-NE vs CRPC-Adeno solid tissue biopsy eRRBS data (Beltran2016)
S2A: PSA and treatment timepoints for the PRIME cohort
S2BPSA and treatment timepoints for the Wu2020 cohort
S3Sequencings statistics for samples profiled with the NEMO panel (Notice that sequencing run and Dataset might differ)
S4: NEMO tumor content (TC) and PE score estimation of all study samples (NEMO generated and reprocessed data)
S5: Association between gene expression and proximal DNA methylation for the PDX EPIC cohort (pdx) and WCDT cohort (biopsies)
S6A: Alisertib cohort survival data
S6B: Chemo trial cohort survival data
S7: Inclusion criteria for the two phase 2 trial cohorts
S8:References of masked samples and samples sequenced in this work
S9: Description of informative regions included in the NEMO panel
S10: Mean CpG coverage in NEMO regions for reprocessed data (only CpG sites with at least 10x coverage are retained)